Please assess the completion status of the following clinical trial:

Trial Title: Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All women completing NCT01440803 who remain without a disease or medication that causes osteoporosis will be offered enrollment into this study.~* (Premenopausal status is no longer be required for entry.)~Exclusion Criteria:~* Renal insufficiency or liver disease: Creatinine, transaminase (AST)/alanine transaminase (ALT) above upper limit of normal~* Vitamin D deficiency: 25-hydroxyvitamin D (25-OHD) \<30 ng/mL~* Pregnancy: urine pregnancy test must be negative

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: EXPERIMENTAL): Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).